Cingulate Announces Closing of $7.5 Million Public Offering
February 06, 2024 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Announces Pricing of $7.5 Million Public Offering
February 02, 2024 09:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Superblock to Provide Monthly Blockchain Reports on Bloomberg Terminal
January 29, 2024 09:00 ET
|
Superblock
SEOUL, South Korea, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Superblock, the main contributor of the ‘Over Protocol’ mainnet, provides a blockchain insight report to Bloomberg Terminal. Superblock...
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
January 29, 2024 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Nano Dimension Announces Preliminary All Cash Proposal to Acquire Stratasys for $16.50 per share
December 23, 2023 09:00 ET
|
Nano Dimension Ltd.
Waltham, Mass., Dec. 23, 2023 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension”, or “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics...
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
December 01, 2023 09:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
MEF Launches Enterprise Leadership Council with Esteemed Corporate Leaders
October 03, 2023 08:10 ET
|
MEF
MEF formed a council of senior executives from all major enterprise vertical markets to bring important end user perspective and involvement to MEF.
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
September 11, 2023 06:00 ET
|
Cingulate Inc.
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend...
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 05, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Bloomberg Philanthropies and the Aspen Institute Announce Bloomberg CityLab 2023 in Washington, D.C.
August 28, 2023 09:00 ET
|
The Aspen Institute
New York, NY and Washington, D.C., Aug. 28, 2023 (GLOBE NEWSWIRE) -- The tenth Bloomberg CityLab, the preeminent global cities summit organized by Bloomberg Philanthropies in partnership with the...